

St. Louis, Missouri — 1998 (N=226)

Figure A. Age of GISP participants, in years, 1998




Figure B. Race/ethnicity of GISP participants, 1998




Figure C. Percentage of GISP participants Identifying as men who have sex with men






Figure D. Reason for visit among GISP participants, 1998




St. Louis, Missouri — 1998 (N=226)

Figure E. Previous episode of gonorrhea among GISP participants




Note: Data points not shown when >30% data missing.

Figure G. Resistance to penicillin and tetracycline among GISP isolates, 1998




Pen & Tet Suscep PPNG
 PPNG/TRNG PenR
 CMRNG TRNG
 TetR

Figure F. Treatment given to GISP participants, 1998



Cefixime Ciprofloxacin
 None Other

Figure H. Ceftriaxone minimum inhibitory concentrations (MIC) among GISP isolates, 1998



St. Louis, Missouri — 1998 (N=226)

Figure I. Cefixime minimum inhibitory concentrations (MIC) among GISP isolates, 1998





Figure J. Intermediate resistance and resistance to ciprofloxacin among GISP isolates



Note: Susceptibility to ciprofloxacin first measured in 1990.

Figure K. Ciprofloxacin minimum inhibitory concentrations (MIC) among GISP isolates, 1998

